Dyne Therapeutics, Inc. - Common Stock (DYN)
13.82
-0.59 (-4.09%)
NASDAQ · Last Trade: Jun 16th, 10:04 PM EDT
Via Benzinga · June 16, 2025
Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics.
Via Chartmill · June 16, 2025
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly.
Via Investor's Business Daily · April 21, 2025
Via Benzinga · April 11, 2025
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risksbenzinga.com
On Tuesday, BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ...
Via Benzinga · March 12, 2025
JP Morgan analysts question Dyne Therapeutics' strategy for DYNE-101 in DM1, highlighting regulatory uncertainty and investor concerns over data updates.
Via Benzinga · March 21, 2025

Dyne Therapeutics' DYNE-101 shows promising Phase 1/2 results for myotonic dystrophy type 1, with plans for Accelerated Approval by 2026.
Via Benzinga · January 10, 2025

Via Benzinga · September 30, 2024

Dyne Therapeutics revealed new clinical data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy, showing significant increases in dystrophin expression and meaningful functional improvements.
Via Benzinga · September 3, 2024

Via Benzinga · September 3, 2024

The company is hoping to rival Sarepa's Exondys 51. But three executives just departed on what is calls "unprecedented" test results.
Via Investor's Business Daily · September 3, 2024

Via Benzinga · September 3, 2024

Via Benzinga · September 3, 2024
Find out the significance of the
Via Talk Markets · August 21, 2024

A wave of bullish sentiment swept through Wall Street on Tuesday after lower-than-expected producer inflation data solidified expectations for Federal Reserve rate cuts, prompting speculators to increase bets on a more significant 50
Via Benzinga · August 13, 2024

DYN stock results show that Dyne Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 12, 2024

10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit Therapeutics, Plug Power and XPeng Inc.
Via Benzinga · July 14, 2024
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States.
Via Talk Markets · July 10, 2024

Via Benzinga · June 12, 2024

U.S. inflation slowed in May, boosting rate cut prospects. Markets rally ahead of FOMC meeting and assign 70% chance of rate cut in September.
Via Benzinga · June 12, 2024

https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate
Via InvestorPlace · June 4, 2024